• 1. Evolutionary approaches in protein engineering towards biomaterial construction
  Brindha J.,Balamurali M. M.,Kaushik Chanda RSC Adv., 2019,9, 34720-34734
• 2. Evolution and characterization of a benzylguanine-binding RNA aptamer?
  J. Xu,T. J. Carrocci,A. A. Hoskins Chem. Commun., 2016,52, 549-552
• 3. Dissociative electron attachment to HGaF4 Lewis–Br?nsted superacid
  Marcin Czapla,Jack Simons Phys. Chem. Chem. Phys., 2018,20, 21739-21745
• 4. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 5. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Prenol lipids Triterpene saponins

Niga-ichigoside F1: A Comprehensive Overview

Niga-ichigoside F1, also known by its CAS registry number CAS No. 95262-48-9, is a naturally occurring compound that has garnered significant attention in the fields of pharmacology and natural product research. This compound is a triterpenoid saponin, a class of molecules known for their diverse biological activities. Recent studies have highlighted its potential in various therapeutic applications, making it a subject of intense scientific investigation.

The structural elucidation of Niga-ichigoside F1 has been a focal point of research, with scientists employing advanced spectroscopic techniques such as NMR and MS to determine its precise structure. This compound is characterized by a glycosidic linkage between a triterpene aglycone and one or more sugar moieties, which contributes to its unique pharmacological properties. The aglycone portion is particularly significant, as it is responsible for many of the compound's bioactive effects.

One of the most promising areas of research involving Niga-ichigoside F1 is its potential anti-inflammatory activity. Recent studies have demonstrated that this compound can inhibit the production of pro-inflammatory cytokines such as TNF-α and IL-6, which are key players in chronic inflammatory diseases. These findings suggest that Niga-ichigoside F1 could be a valuable addition to the arsenal of anti-inflammatory agents currently available.

In addition to its anti-inflammatory properties, Niga-ichigoside F1 has also been investigated for its antioxidant capabilities. Oxidative stress is a major contributor to various pathological conditions, including cardiovascular diseases and neurodegenerative disorders. Research indicates that this compound can scavenge free radicals and reduce oxidative damage, thereby offering protection against these conditions.

The antiproliferative effects of Niga-ichigoside F1 on cancer cells have also been explored in recent studies. Experimental data show that this compound can induce apoptosis in cancer cells while sparing normal cells, indicating its potential as an anticancer agent. These findings are particularly significant given the growing need for targeted therapies with minimal side effects.

The mechanism of action of Niga-ichigoside F1 involves multiple pathways, including modulation of the NF-kB signaling pathway and activation of caspases, which are critical for apoptosis regulation. Understanding these mechanisms is essential for developing therapeutic strategies that harness the full potential of this compound.

From an application standpoint, Niga-ichigoside F1 holds promise in the development of functional foods, nutraceuticals, and pharmaceuticals. Its bioavailability and stability under physiological conditions are critical factors being investigated to ensure its efficacy in real-world applications.

In conclusion, Niga-ichigoside F1, with its CAS number CAS No. 95262-48-9, represents a compelling candidate for drug development due to its multifaceted biological activities. As research continues to uncover new insights into its mechanisms and applications, this compound is poised to make significant contributions to the field of natural product-based therapeutics.

• 119108-20-2(Urs-12-en-28-oic acid,3-[(4-O-acetyl-a-L-arabinopyranosyl)oxy]-19-hydroxy-,b-D-glucopyranosyl ester, (3b)- (9CI))
• 146445-81-0(Urs-12-en-28-oic acid, 3-[(2-O-acetyl-3-O-β-D-glucopyranosyl-α-L-arabinopyranosyl)oxy]-19,21-dihydroxy-, β-D-glucopyranosyl ester, (3β,21α)- (9CI))
• 146445-78-5(Urs-12-en-28-oic acid,3-(a-L-arabinopyranosyloxy)-19,21-dihydroxy-,b-D-glucopyranosyl ester, (3b,21a)- (9CI))
• 165198-40-3(Urs-12-en-28-oic acid, 3-(b-D-glucopyranosyloxy)-19-hydroxy-,b-D-glucopyranosyl ester, (3b)- (9CI))
• 146713-88-4(Urs-12-en-28-oic acid, 3-[(O-β-D-glucopyranosyl-(1→2)-O-[β-D-glucopyranosyl-(1→3)]-α-L-arabinopyranosyl)oxy]-19-hydroxy-, β-D-glucopyranosyl ester, (3β)- (9CI))
• 146713-87-3(Urs-12-en-28-oic acid,19-hydroxy-3-[(O-b-D-xylopyranosyl-(1®2)-O-b-D-glucopyranosyl-(1®3)-2-O-acetyl-a-L-arabinopyranosyl)oxy]-, b-D-glucopyranosyl ester, (3b)- (9CI))
• 145854-08-6(Urs-12-en-28-oic acid, 3-[(3-O-β-D-glucopyranosyl-α-L-arabinopyranosyl)oxy]-19-hydroxy-, O-6-deoxy-α-L-mannopyranosyl-(1→2)-O-[β-D-glucopyranosyl-(1→6)]-β-D-glucopyranosyl ester, (3β)- (9CI))
• 147235-21-0(Urs-12-en-28-oic acid,3-(a-L-arabinopyranosyloxy)-19,23-dihydroxy-,b-D-glucopyranosyl ester, (3b,4a)- (9CI))
• 145854-06-4(Urs-12-en-28-oic acid,3,19-dihydroxy-, O-6-deoxy-a-L-mannopyranosyl-(1®2)-O-[b-D-xylopyranosyl-(1®6)]-b-D-glucopyranosyl ester, (3b)- (9CI))
• 145022-80-6(Urs-12-en-28-oic acid, 3-(α-L-arabinopyranosyloxy)-19-hydroxy-, 2-O-(6-deoxy-α-L-mannopyranosyl)-β-D-glucopyranosyl ester, (3β)- (9CI))